For research use only. Not for therapeutic Use.
Naldemedine Tosylate(CAT: I033024) is a peripherally acting μ-opioid receptor antagonist (PAMORA) widely used in gastrointestinal and pain management research. It is specifically designed to alleviate opioid-induced constipation (OIC) without affecting central opioid analgesia. Naldemedine Tosylate works by blocking opioid receptors in the gastrointestinal tract, reducing side effects associated with opioid therapy. Researchers utilize this compound to explore therapeutic strategies for managing OIC and improving the quality of life in patients undergoing long-term opioid treatment. With its high efficacy and targeted mechanism of action, Naldemedine Tosylate is an essential tool for preclinical and clinical studies focused on opioid receptor pharmacology.
CAS Number | 1345728-04-2 |
Synonyms | S 297995; S-297995; S297995; S 297,995; S-297,995; S297,995; Naldemedine; Naldemedine tosylate; Symproic; |
Molecular Formula | C39H42N4O9S |
Purity | 98% |
Target | Neuronal Signaling |
Solubility | Soluble in DMSO |
Appearance | Solid powder |
Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
IUPAC Name | Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-N-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-, 4-methylbenzenesulfonate (1:1) |
InChI | InChI=1S/C32H34N4O6.C7H8O3S/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17;1-6-2-4-7(5-3-6)11(8,9)10/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39);2-5H,1H3,(H,8,9,10)/t22-,26+,31+,32-;/m1./s1 |
InChIKey | WCYDLROFMZJJLE-RTMHEQJQSA-N |
SMILES | O=C(C1=C(O)[C@@]2([H])[C@]34C5=C(O2)C(O)=CC=C5C[C@@H](N(CC6CC6)CC4)[C@]3(O)C1)NC(C7=NC(C8=CC=CC=C8)=NO7)(C)C.O=S(C9=CC=C(C)C=C9)(O)=O |